Viatris Inc. vs Jamjoom Pharmaceuticals Factory Co.
A head-to-head of Viatris Inc. (VTRS) and Jamjoom Pharmaceuticals Factory Co. (4015) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | VTRS | 4015 |
|---|---|---|
| Market Cap | $20.14B | 11.05B SAR |
| P/E (TTM) | — | 22.16 |
| Forward P/E | 6.17 | — |
| P/S | 1.32 | 7.25 |
| P/B | 1.48 | 5.95 |
| EV/EBITDA | 7.62 | 20.41 |
| Dividend Yield | 2.56% | 253.00% |
| Profit Margin | -2.04% | 31.16% |
| Gross Margin | 35.06% | 62.56% |
| Operating Margin | 1.77% | 31.82% |
| Revenue Growth (YoY) | +8.07% | +5.21% |
| FCF Yield | 8.62% | 2.33% |
| Debt / Equity | 97.84 | 1.20 |
| Current Ratio | 1.60 | 4.94 |
Which is better: Viatris Inc. or Jamjoom Pharmaceuticals Factory Co.?
- ✓Larger by market cap: Viatris Inc.
- ✓Higher dividend yield: Jamjoom Pharmaceuticals Factory Co.
- ✓More profitable (net margin): Jamjoom Pharmaceuticals Factory Co.
- ✓Faster revenue growth: Viatris Inc.
- ✓Higher free-cash-flow yield: Viatris Inc.
Across 11 available metrics, Jamjoom Pharmaceuticals Factory Co. leads 6–5.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Viatris Inc. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.